Industry Standard Research (ISR) announced the release of two new reports focused on the Biosimilar industry. “US Payers and Biosimilar Formulary Placement” and “Biosimilars: A View from the Pharmacy” expand the base of knowledge regarding Biosimilar market dynamics. These reports look at how these two segments of the healthcare delivery system view, among other things, Biosimilar pricing, formulary placement, pharmacy-level substitution, and clinical trial requirements.
“This is our third installment in our Biosimilar Primer series. We are starting to see physicians, pharmacists, and payers having very different views on how they see the landscape of Biosimilars unfolding.” explained Andrew Schafer, President of Industry Standard Research.
One interesting data point from the “US Payers and Biosimilar Formulary Placement” report is that while very few payer organizations have a separate formulary tier for Biosimilars today, in two years the adoption of a separate tier is expected to climb substantially.
These reports provide pharmaceutical companies, contract research organizations, marketing, and consulting companies with baseline views of how these constituents view some major topics relating to Biosimilars. The data contained in all three of ISR’s Biosimilar Primer series can be used as foundational elements for an organization’s strategic planning around Biosimilars.
“The Biosimilar market is one that is obviously heating up. We have seen several recent announcements around development programs and/ or partnerships designed to develop and commercialize Biosimilars. ISR will continue to monitor this industry and we are planning a Patient Recruitment in Biosimilar Trials report later this year to help round out our subscriber’s knowledge base.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.